RT Journal Article
SR Electronic
T1 The effects of physiotherapy programs in COVID-19 patients during admission in the hospital
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.27.23285094
DO 10.1101/2023.01.27.23285094
A1 Jianramas, Netchanok
A1 Nissapatorn, Veeranoot
A1 Sivakorn, Chaisith
A1 de Lourdes Pereira, Maria
A1 Ratnarathon, Anuttra (Chaovavanich)
A1 Salesingh, Chenpak
A1 Jaiyen, Eittipad
A1 Chaiyakul, Salinee
A1 Piya-amornphan, Nitita
A1 Semphuet, Thanaporn
A1 Thiangtham, Thanrada
A1 Boontam, Kornchanok
A1 Longlalerng, Khomkrip
YR 2023
UL http://medrxiv.org/content/early/2023/01/28/2023.01.27.23285094.abstract
AB Background and aims Several recommendations exist regarding the role of physiotherapy programs (PTPs) in COVID-19 patients. However, none of the studies examines the frequency of bedside PTPs during admission. Thus, this study aimed to compare the different bedside PTPs frequencies on the survival rate, length of hospitalization (LoH), referrals to the intensive care unit (ICU), and in-hospital complications. The safety of patients and the physiotherapist was also investigated.Methods Fifty-two COVID-19 patients were equally assigned into two groups matched on gender and age (1:1 ratio). Experimental group one received 1-2 times of PTPs during hospitalization, and experimental group two received daily PTPs until hospital discharge. The primary outcomes were the survival rate, LoH, referrals to ICU, and in-hospital complications. The secondary outcomes were the adverse events for patients and the number of physiotherapists who contracted with COVID-19.Results Most participants were classified as having mild to moderate COVID-19 with a mean age of 45 years. There were no differences between groups in all primary outcome measures (all p > 0.05). The overall survival rate was 98%. One participant from the Ex-G2 group was referred to the ICU. Two Ex-G1 and four Ex-G2 participants had complications. There were no immediate serious adverse events found after PTPs for both groups. None of the physiotherapists tested positive for COVID-19.Conclusion In COVID-19 patients with mild to moderate conditions, one to two bedside PTPs were enough to achieve the same results as patients who received daily PTPs. PTPs were safe for COVID-19 patients, and physiotherapists.CLINICAL REGISTRATION NUMBER Thai Clinical Trials, https://www.thaiclinicaltrials.org/, TCTR20210823004.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTCTR20210823004.Funding StatementKhomkrip Longlalerng derived fund from the Health Systems Research Institute of Thailand (HSRI-64-184) (URL: https://www.hsri.or.th/researcher). Maria de Lourdes Pereira received fund from the Project CICECO-Aveiro Institute of Materials, UIDB/50011/2020, UIDP/50011/2020 & LA/P/0006/2020, financed by national funds through the FCT/MEC (PIDDAC)(URL: https://www.ua.pt/en/news/0/46235). NO - Include this sentence at the end of your statement: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The technical approval was granted by the Human Research Ethics Committee of the Bamrasnaradura Infectious Disease Institute, Nonthaburi Province (S020h/64), and the Human Research Ethics Committee of Walailak University, Nakhon Si Thammarat Province (WU-EC-AL-3-186-64).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.